STOCK TITAN

American Healthcare REIT (NYSE: AHR) names Jeff Hanson CEO and elevates key leaders

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

American Healthcare REIT, Inc. announced CEO and leadership changes. Danny Prosky retired as Chief Executive Officer and President effective July 21, 2026, will remain on the board, and receives severance benefits under the existing Severance and Change in Control Plan, a $35,000 lump-sum payment, and accelerated vesting of a 2024 restricted stock award pursuant to a release of claims.

The board appointed Jeff Hanson, previously Interim CEO and Chairman, as permanent CEO with a $965,000 base salary, target annual bonus equal to 160% of base salary, and time-based and performance-based RSU grants each with a grant date fair value of $2,072,534, subject to multi‑year vesting and performance conditions. COO Gabe Willhite was promoted to President and COO with a $100,000 cash compensation increase, a higher bonus target of 125% of annualized base compensation, and time- and performance-based RSUs each valued at $347,840. Director Scott Estes was named Lead Independent Director with an additional $40,000 annual cash retainer, and a press release describing these changes was furnished as an exhibit.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
CEO base salary $965,000 Annual base salary for Jeff Hanson as Chief Executive Officer
CEO target bonus 160% of base salary Target annual bonus opportunity for Jeff Hanson
Time-based RSU grant to CEO $2,072,534 Grant date fair value of time-based RSUs vesting over three years from July 21, 2026
Performance-based RSU grant to CEO $2,072,534 Grant date fair value of performance-based RSUs cliff-vesting on December 31, 2028
President RSU grants (time-based) $347,840 Grant date fair value of time-based RSUs to Gabe Willhite vesting over three years from March 10, 2026
President RSU grants (performance-based) $347,840 Grant date fair value of performance-based RSUs to Gabe Willhite cliff-vesting on December 31, 2028
Prosky lump-sum payment $35,000 Lump-sum payment acknowledging expected continuation medical coverage expenses under release agreement
Lead Independent Director retainer $40,000 Additional annual cash retainer for Scott Estes as Lead Independent Director
performance-based RSUs financial
"a grant of performance-based RSUs with a grant date fair value"
Performance-based restricted stock units (RSUs) are promises to deliver company shares to employees only if the business meets specific goals, such as revenue, profit, stock-price targets, or strategic milestones. For investors, they matter because they change future share supply and align management incentives with company results—like a salesperson whose bonus only pays out when sales targets are hit—so they can affect earnings, dilution, and confidence in leadership.
cliff-vesting financial
"subject to cliff-vesting on December 31, 2028 based upon performance conditions"
Lead Independent Director financial
"the Board appointed Scott A. Estes as Lead Independent Director"
A lead independent director is a board member who is not part of company management and is chosen to coordinate and represent the other independent directors, often running sessions without the CEO, helping set meeting agendas, and serving as a liaison between shareholders and the board. For investors, this role signals stronger, more balanced oversight—like a neutral referee who helps ensure decisions are fair, transparent and focused on protecting shareholder interests.
Severance and Change in Control Plan financial
"benefits in accordance with Section 3.3 of the Executive Severance and Change in Control Plan"
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure describes the furnished press release"
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What leadership changes did American Healthcare REIT (AHR) announce?

American Healthcare REIT announced that Danny Prosky retired as CEO and President, Jeff Hanson became permanent CEO, Gabe Willhite was promoted to President and COO, and Scott Estes was appointed Lead Independent Director, all effective July 21, 2026.

What is Jeff Hanson’s compensation package as CEO of AHR?

Jeff Hanson will receive a $965,000 annual base salary, a target annual bonus equal to 160% of base salary, and time-based and performance-based RSU grants each with a grant date fair value of $2,072,534, subject to multi-year vesting and performance conditions.

What retirement benefits will Danny Prosky receive from AHR?

Danny Prosky will receive benefits under the existing Severance and Change in Control Plan, a $35,000 lump-sum payment to acknowledge expected medical coverage expenses, and accelerated vesting of the unvested portion of his February 9, 2024 restricted stock award, which was originally scheduled to vest February 9, 2028.

How is Gabe Willhite’s compensation changing with his promotion at AHR?

With his promotion to President and COO, Gabe Willhite receives a $100,000 increase in cash compensation, a higher target cash bonus of 125% of annualized base compensation, and new time-based and performance-based RSU grants each with a grant date fair value of $347,840, subject to multi-year vesting.

What additional compensation will Scott Estes receive as Lead Independent Director at AHR?

Scott Estes, a non-employee director, has been appointed Lead Independent Director and will receive an additional annual cash retainer of $40,000, reflecting his expanded governance role alongside his ongoing board and audit committee responsibilities.

Did American Healthcare REIT (AHR) issue a press release about these leadership changes?

Yes. The company issued a press release on July 22, 2026 detailing the CEO transition, executive promotions, and Lead Independent Director appointment. This press release was furnished as Exhibit 99.1 and is not deemed filed for Exchange Act liability purposes.
false000163297000016329702026-07-202026-07-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 20, 2026

 

 

American Healthcare REIT, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Maryland

001-41951

47-2887436

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

18191 Von Karman Avenue, Suite 300

 

Irvine, California

 

92612

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 949 270-9200

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.01 par value per share

 

AHR

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.

 

Chief Executive Officer Transition

 

On July 20, 2026, Danny Prosky notified American Healthcare REIT, Inc. (the “Company”) of his decision to retire as Chief Executive Officer and President of the Company, effective as of July 21, 2026. Mr. Prosky will continue to serve as a member of the board of directors of the Company (the “Board”), and will commence participation in the Company’s non-employee director compensation program following such retirement.

 

In connection with Mr. Prosky’s retirement, he will be entitled to receive benefits in accordance with Section 3.3 of the American Healthcare Opps Holdings, LLC Executive Severance and Change in Control Plan (the “Severance Plan”), a copy of which is attached as Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 25, 2022.

 

In addition, the Company, American Healthcare Opps Holdings, LLC and Mr. Prosky entered into a release of claims agreement, dated July 21, 2026, in favor of the Company and its affiliates (the “Release Agreement”), pursuant to which Mr. Prosky will be entitled to receive (i) in acknowledgment of the expenses that Mr. Prosky is expected to incur with respect to continuation coverage under the Company’s medical plans, a lump sum payment of $35,000, and (ii) accelerated vesting of the unvested portion of his Restricted Stock Award Agreement, granted as of February 9, 2024, and which was scheduled to vest on February 9, 2028.

 

The material terms of the Release Agreement are qualified in their entirety by the Release Agreement attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

On July 21, 2026, the Board appointed Jeffrey Hanson, who has been serving as the Company’s Interim Chief Executive Officer and President since February 3, 2026, to succeed Mr. Prosky as Chief Executive Officer of the Company, effective July 21, 2026. He will also continue to serve as Chairman of the Board. Biographical information for Mr. Hanson may be found in the Company’s Definitive Proxy Statement relating to the Company’s 2026 Annual Meeting of Stockholders filed with the SEC on April 9, 2026.

 

In connection with Mr. Hanson’s promotion, upon the recommendation of the Compensation Committee of the Board (the “Compensation Committee”), the Board approved the following compensation terms for Mr. Hanson: (i) an annual base salary of $965,000; (ii) a target annual bonus opportunity equal to 160% of Mr. Hanson’s annualized base salary; (iii) a grant of time-based restricted stock units (“RSUs”) with a grant date fair value of $2,072,534, which are scheduled to vest in three equal annual installments on the first three anniversaries of July 21, 2026; (iv) a grant of performance-based RSUs with a grant date fair value of $2,072,534, subject to cliff-vesting on December 31, 2028 based upon the satisfaction of applicable performance conditions consistent with the corporate performance goals approved for the Company’s named executive officers for the performance period beginning on January 1, 2026 and ending on December 31, 2028; and (v) eligibility for severance benefits in the event Mr. Hanson’s employment is terminated in connection with a change in control of the Company under Section 3.2 of the Severance Plan. Vesting of the promotion equity grants is subject to Mr. Hanson remaining as an executive officer or director of the Board through the applicable vesting dates. In addition, in connection with Mr. Hanson’s promotion, the Compensation Committee clarified that Mr. Hanson’s continued service as the Company’s permanent Chief Executive Officer will constitute continued service for purposes of determining the vesting of Mr. Hanson’s equity awards that he received on March 26, 2026 in connection with his appointment to the position of Interim Chief Executive Officer.

 

Promotion of Chief Operating Officer

 

On July 21, 2026, the Board appointed the Company’s current Chief Operating Officer, Gabe Willhite, to the position of President and Chief Operating Officer, effective July 21, 2026. Biographical information for Mr. Willhite may be found in the Company’s Definitive Proxy Statement relating to the Company’s 2026 Annual Meeting of Stockholders filed with the SEC on April 9, 2026. In connection with Mr. Willhite’s promotion, he will be entitled to receive: (i) an increase in cash compensation of $100,000; (ii) an increase in target cash bonus to 125% of annualized base compensation; (iii) a grant of time-based RSUs with a grant date fair value of $347,840, which are scheduled to vest in three equal annual installments on the first three anniversaries of March 10, 2026; and (iv) a grant of performance-based RSUs with a grant date fair value of $347,840, subject to cliff-vesting on December 31, 2028 based upon the satisfaction of applicable performance conditions consistent with the corporate performance goals approved for the Company’s named executive officers for the performance period beginning on January 1, 2026 and ending on December 31, 2028.


 

Appointment of Lead Independent Director

 

On July 21, 2026, the Board appointed Scott A. Estes, a current non-employee director of the Company, as Lead Independent Director, effective July 21, 2026. In connection with such appointment, Mr. Estes will receive an additional annual cash retainer of $40,000. Biographical information for Mr. Estes may be found in the Company’s Definitive Proxy Statement relating to the Company’s 2026 Annual Meeting of Stockholders filed with the SEC on April 9, 2026.

Item 7.01 Regulation FD Disclosure.

On July 22, 2026, we issued a press release relating to the matters described in Item 5.02 above. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 7.01, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

 

Description

10.1

 

Release of Claims Agreement, dated July 21, 2026, by and among, American Healthcare REIT, Inc., American Healthcare Opps Holdings, LLC and Danny Prosky

99.1

 

American Healthcare REIT, Inc. Press Release, July 22, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

American Healthcare REIT, Inc.

 

 

 

 

Date:

July 22, 2026

By:

/s/ Jeffrey T. Hanson

 

 

 

Name: Jeffrey T. Hanson
Title: Chief Executive Officer

 

 


Exhibit 99.1

img32265050_0.jpg

American Healthcare REIT Announces Leadership Appointments

Jeff Hanson Named CEO; Gabe Willhite Elevated to President; Danny Prosky Retires as CEO, Continues as Director; Scott Estes Named Lead Independent Director

IRVINE, Calif., July 22, 2026 – American Healthcare REIT, Inc. (NYSE: AHR) (the “Company”) today announced leadership appointments that build on a decade of stability while accelerating the Company’s focus on platform-enhancing strategies as it enters its next phase of growth and value creation for stockholders.

Effective immediately:

Jeff Hanson has been named the Company’s Chief Executive Officer, while he continues in his role as Chairman of the Board.
Gabe Willhite has been elevated to President, in addition to his ongoing role as Chief Operating Officer.
Danny Prosky, who had served as President and Chief Executive Officer since the Company’s formation, has retired from his executive role and continues to serve as a member of the Board of Directors and as an advisor to the management team.
Scott Estes, an independent member of the Board of Directors, has been appointed Lead Independent Director.

Hanson had served as Interim Chief Executive Officer since February 2026, when Prosky began a medical leave of absence following a serious health event. After thoughtful consideration, Prosky has elected to step back from day-to-day executive responsibilities. The Board of Directors has appointed Hanson, a co-founder of the Company who has served as Chairman of the Board since its formation, to continue in the Chief Executive Officer role.

 


 

“In light of Danny’s decision to retire following a remarkable recovery and a tremendous 35-year career marked by excellence at every turn, I am honored to serve the Company as CEO, and I do so with great confidence in the depth of leadership we have established across this organization,” Hanson said. “Danny, Mathieu Streiff and I built this platform together over the past two decades, and Danny’s extraordinary leadership leaves an indelible mark for which we are profoundly grateful. His continued involvement as a director and trusted advisor is deeply appreciated by our Board of Directors and every employee of American Healthcare REIT.”

“Although my recovery has gone exceedingly well, I am fortunate that AHR’s depth gives me the flexibility to prioritize my family at this stage of my life. This Company is strong, the strategy is delivering industry-leading results, and the senior leadership team is exceptional,” Prosky said. “I remain fully engaged as a director and advisor to the executive management team, and I am deeply grateful to our employees, our operating partners, our Board of Directors and our shareholders for their trust over so many years.”

Willhite has been with the Company and its predecessors since 2016, when he joined as Senior Vice President, Assistant General Counsel. He was promoted to Executive Vice President, General Counsel in 2020 and then to Chief Operating Officer in 2022.

“Gabe’s elevation to President recognizes a decade of consistent performance and enterprise leadership. He has earned the confidence of our Board, the senior management team, and our key partners,” said Hanson. “His expanded role positions him to take on broader operational responsibility, specifically focused on strategies to further scale the platform. While we are proud of what this team has built, we remain focused on ensuring that the best version of this company is ahead of us.”

Willhite added: “I am honored by the Board’s confidence and am grateful for the opportunity to serve the Company in this expanded role. We are in the early stages of a generational investment opportunity in the senior housing sector, and I am excited to help lead the Company through such a dynamic and transformative period.”

 


 

Lead Independent Director Appointment

The Board of Directors has appointed Scott Estes, who has served as an independent director of the Company since August 2022 and Chair of the Audit Committee since June 2023, as Lead Independent Director. Estes is the former Chief Financial Officer of Welltower Inc. (NYSE: WELL), where he served from 2006 to 2017 and led capital markets activity that raised more than $24 billion in equity and unsecured debt capital. He also currently serves as Chairman of the Board of Essential Properties Realty Trust (NYSE: EPRT) and as a member of the Board of Trustees and Audit Committee Chair of JBG SMITH Properties (NYSE: JBGS). Estes’ appointment as Lead Independent Director is an acknowledgment of his exemplary leadership and reflects the Company’s continued commitment to strong corporate governance.

“This transition reflects thoughtful planning and the strength of leadership that has been built,” Estes said. “Since I joined the Board in 2022, I have been extraordinarily impressed with the results delivered by AHR’s senior management and their strategic vision. The Board has full confidence in the team, and I look forward to supporting the continued execution of our business plan as Lead Independent Director.”

About American Healthcare REIT, Inc.

American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns and operates a diversified portfolio of clinical healthcare real estate, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, and in the United Kingdom and the Isle of Man.

SOURCE American Healthcare REIT, Inc.

Investor Contact:

Alan Peterson

VP, Investor Relations & Finance

(949) 270-9200

investorrelations@ahcreit.com

 

Media Contact:

Damon Elder

Spotlight Marketing Communications

(949) 427-1377

damon@spotlightmarcom.com

 

 


Filing Exhibits & Attachments

3 documents